Patents by Inventor Boerries BRANDENBURG
Boerries BRANDENBURG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11905314Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: GrantFiled: July 26, 2022Date of Patent: February 20, 2024Assignee: Janssen Vaccines & Prevention B.V.Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina Jongeneelen, Daphné Truan, Johannes Petrus Maria Langedijk
-
Publication number: 20230312654Abstract: Provided herein are isolated mutant influenza hemagglutinin polypeptides, methods for providing isolated mutant hemagglutinin polypeptides, compositions comprising the same, vaccines comprising the same and methods of their use, in particular in the detection, prevention and/or treatment of influenza.Type: ApplicationFiled: October 15, 2020Publication date: October 5, 2023Inventors: Boerries BRANDENBURG, Johannes Petrus Maria LANGEDIJK, Tina RITSCHEL, Ferdinand Jacobus MILDER, Mandy Antonia Catharina JONGENEELEN
-
Publication number: 20230250135Abstract: Provided herein are group 2 influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: ApplicationFiled: September 3, 2020Publication date: August 10, 2023Inventors: Mandy Antonia Catharina JONGENEELEN, Tina RITSCHEL, Ferdinand Jacobus MILDER, Indigo KING, Yifan SONG, Johannes Petrus Maria LANGEDIJK, Boerries BRANDENBURG
-
Publication number: 20220411474Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: ApplicationFiled: July 26, 2022Publication date: December 29, 2022Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina JONGENEELEN, Daphné Truan, Johannes Petrus Maria Langedijk
-
Patent number: 11447526Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: GrantFiled: January 22, 2019Date of Patent: September 20, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Ferdinand Jacobus Milder, Tina Ritschel, Boerries Brandenburg, Mandy Antonia Catharina Jongeneelen, Daphné Truan, Johannes Petrus Maria Langedijk
-
Publication number: 20220204567Abstract: The invention provides recombinant influenza A hemagglutinin (HA) polypeptides, comprising an HA1 and a HA2 domain of an influenza A virus HA, and comprising an amino acid sequence wherein: (a) the amino acid at position 355 is W; and (b) the amino acid at position 432 is I and/or the amino acid at position 380 is I; and wherein the numbering of the amino acid positions in the amino acid sequence of the HA polypeptide is according to the numbering of amino acids in the amino acid sequence of HA from a reference H3N2 influenza strain, in particular the reference strain H3N2 A/Aichi/2/68 (SEQ ID NO: 1), immunogenic fragments thereof, nucleic acid molecules encoding said polypeptides or immunogenic fragments, and uses thereof.Type: ApplicationFiled: April 23, 2020Publication date: June 30, 2022Inventors: Boerries BRANDENBURG, Tina RITSCHEL, Ferdinand Jacobus MILDER, Mandy Antonia, Catharina JONGENEELEN, Indigo KING, Yifan SONG, Johannes Petrus, Maria LANGEDIJK
-
Patent number: 11136379Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: GrantFiled: June 5, 2020Date of Patent: October 5, 2021Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
-
Publication number: 20200377555Abstract: Provided herein are influenza hemagglutinin stem polypeptides, nucleic acids encoding said polypeptides, vectors comprising said nucleic acid and pharmaceutical compositions comprising the same, as well as methods of their use, in particular in the prevention and/or treatment of influenza virus infections.Type: ApplicationFiled: January 22, 2019Publication date: December 3, 2020Inventors: Ferdinand Jacobus MILDER, Tina RITSCHEL, Boerries BRANDENBURG, Mandy Antonia Catharina JONGENEELEN, Daphné TRUAN, Johannes Petrus Maria LANGEDIJK
-
Publication number: 20200299364Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: ApplicationFiled: June 5, 2020Publication date: September 24, 2020Inventors: Boerries BRANDENBURG, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
-
Patent number: 10738083Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.Type: GrantFiled: May 10, 2016Date of Patent: August 11, 2020Assignee: Janssen Vaccines & Prevention B.V.Inventors: Maria Van Dongen, Christophe Francis Robert Nestor Buyck, Wim Bert Griet Schepens, Jaroslaw Juraszek, Bart Rudolf Romanie Kesteleyn, Pierre Jean-Marie Bernard Raboisson, Boerries Brandenburg
-
Patent number: 10703804Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: GrantFiled: June 27, 2019Date of Patent: July 7, 2020Assignee: Janssen Vaccines & Prevention B.V.Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
-
Publication number: 20200048308Abstract: The present invention relates to novel compounds, in particular peptidic macrocyclic peptides, that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses comprising HA of the H1 subtype 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic 5 compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.Type: ApplicationFiled: October 26, 2017Publication date: February 13, 2020Inventors: Jaroslaw JURASZEK, Maria VAN DONGEN, Boerries BRANDENBURG
-
Publication number: 20190359693Abstract: Multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains comprising HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: ApplicationFiled: June 27, 2019Publication date: November 28, 2019Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
-
Patent number: 10370435Abstract: Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: GrantFiled: February 5, 2016Date of Patent: August 6, 2019Assignee: Janssen Vaccines & Prevention B.V.Inventors: Boerries Brandenburg, Ronald Vogels, Joost A. Kolkman, Robert Heinz Edward Friesen
-
Publication number: 20180118788Abstract: The present invention relates to novel peptidomimetic compounds that are capable of binding to and/or neutralizing influenza viruses, in particular influenza A viruses of phylogenetic group 1, and to pharmaceutical compositions comprising such compounds. The invention also relates to the use of the peptidomimetic compounds in the diagnosis, prophylaxis and/or treatment of influenza virus infections.Type: ApplicationFiled: May 10, 2016Publication date: May 3, 2018Applicant: Janssen Vaccines & Prevention B.V.Inventors: Maria VAN DONGEN, Christophe Francis Robert Nestor BUYCK, Wim Bert Griet SCHEPENS, Jaroslaw JURASZEK, Bart Rudolf Romanie KESTELEYN, Pierre Jean-Marie Bernard RABOISSON, Boerries BRANDENBURG
-
Publication number: 20180016323Abstract: Monomeric and multimeric binding molecules that are capable of specifically binding to hemagglutinin (HA) of at least two influenza A virus strains, said strains including HA of two different HA subtypes from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically binding to hemagglutinin (HA) of at least one influenza B virus strain are provided. The binding molecules preferably are also capable of neutralizing at least two influenza A virus strains from phylogenetic group 2; or capable of neutralizing at least one influenza A virus strain from phylogenetic group 1 and at least one influenza A virus strain from phylogenetic group 2; or capable of specifically neutralizing at least one influenza B virus strain.Type: ApplicationFiled: February 5, 2016Publication date: January 18, 2018Inventors: Boerries BRANDENBURG, Ronald VOGELS, Joost A. KOLKMAN, Robert Heinz Edward FRIESEN